Integrating Lifestyle Interventions and Molecular Profiling into Early-Stage CRC Care

Evidence presented at the NCCN 2026 Annual Conference has solidified the role of structured physical activity and comprehensive molecular testing as standard-of-care components for patients with non-metastatic colorectal cancer (CRC). Jeffrey Meyerhardt, MD, of the Dana-Farber Cancer Institute, presented data confirming that these interventions significantly alter disease-free survival (DFS) and recurrence trajectories in stage 2 and 3 disease.

Exercise as a Prescribed Clinical Intervention

The CO21 trial represents a landmark in behavioral oncology, providing randomized evidence that structured exercise programs (SEP) directly impact survival in patients with colon cancer who have completed adjuvant chemotherapy.

Patients randomized to the SEP cohort demonstrated an 80.3% five-year DFS rate, compared to 73.9% in the health education-only control group. The clinical utility of the intervention is characterized by a number needed to treat (NNT) of 16 to prevent one recurrence and an NNT of 14 to prevent one death.

Nursing Practice Note: The updated NCCN Guidelines now advise oncology teams to facilitate a goal of at least 150 minutes of moderate-to-vigorous physical activity per week.

The Mandate for Molecular Profiling in Early-Stage Disease

While molecular profiling was historically reserved for metastatic disease, the 2026 guidelines now recommend testing for all stage 2 and 3 CRC tumors, allowing for the identification of biomarkers that dictate adjuvant and neoadjuvant strategies.

PIK3CA Mutations and Aspirin Therapy

Data from the ALASCCA trial have confirmed a survival benefit for a specific subset of patients using daily aspirin. This benefit is limited to patients whose tumors harbor a PIK3CA mutation.

"To be able to know if they have a PIK3CA alteration... you need to do testing," Meyerhardt noted during the session. For nurses, this requires ensuring that pathology orders for early-stage patients include comprehensive profiling beyond standard mismatch repair (MMR) status to identify candidates for this low-cost, high-impact adjunct therapy.

Immunotherapy Breakthroughs in dMMR/MSI-H Tumors

For patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, immunotherapy is yielding unprecedented pathologic responses:

• Adjuvant Setting (ATOMIC Study): The addition of atezolizumab (Tecentriq) to standard FOLFOX for stage 3 colon cancer improved 3-year DFS from 76.6% to 86.4%.
• Neoadjuvant Setting (NICHE-2 Study): Immunotherapy administered prior to surgery resulted in a 68% pathological complete response (pCR) rate.
• Rectal Cancer (Dostarlimab): In a study of 42 patients with dMMR rectal cancer, dostarlimab (Jemperli) achieved a 100% clinical complete response rate.

The "Watch and Wait" Paradigm

The 100% response rate observed with dostarlimab in dMMR rectal cancer supports the "watch and wait" surveillance model. This approach allows some patients to avoid the morbidity of radical surgery; however, it requires rigorous follow-up, including frequent endoscopic evaluations and imaging, to ensure sustained remission.

A Holistic, Targeted Future

The 2026 NCCN updates represent a convergence of biological precision and patient-driven lifestyle changes. By integrating molecular biomarkers with structured exercise goals, oncology nurses can provide a more robust defense against recurrence in the early-stage CRC population.

Reference

1. Meyerhardt J. Advances in Early-Stage Colorectal Cancer: Integrating Emerging Evidence into Practice. Presented at: NCCN 2026 Annual Conference; March 2026; Orlando, FL.